vs
Side-by-side financial comparison of CARVANA CO. (CVNA) and Viatris (VTRS). Click either name above to swap in a different company.
CARVANA CO. is the larger business by last-quarter revenue ($5.6B vs $3.7B, roughly 1.5× Viatris). On growth, CARVANA CO. posted the faster year-over-year revenue change (58.0% vs 5.0%). Viatris produced more free cash flow last quarter ($619.3M vs $379.0M). Over the past eight quarters, CARVANA CO.'s revenue compounded faster (35.3% CAGR vs 0.5%).
Carvana Co. is an online used car retailer based in Tempe, Arizona. Carvana was named to the 2021 Fortune 500 list, one of the youngest companies to be added to the list.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
CVNA vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.6B | $3.7B |
| Net Profit | $857.0M | — |
| Gross Margin | 18.8% | 31.1% |
| Operating Margin | 7.6% | -5.2% |
| Net Margin | 15.3% | — |
| Revenue YoY | 58.0% | 5.0% |
| Net Profit YoY | 984.8% | — |
| EPS (diluted) | — | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.6B | $3.7B | ||
| Q3 25 | $5.6B | $3.7B | ||
| Q2 25 | $4.8B | $3.6B | ||
| Q1 25 | $4.2B | $3.2B | ||
| Q4 24 | $3.5B | $3.5B | ||
| Q3 24 | $3.7B | $3.7B | ||
| Q2 24 | $3.4B | $3.8B | ||
| Q1 24 | $3.1B | $3.7B |
| Q4 25 | $857.0M | — | ||
| Q3 25 | $151.0M | — | ||
| Q2 25 | $183.0M | — | ||
| Q1 25 | $216.0M | — | ||
| Q4 24 | $79.0M | — | ||
| Q3 24 | $85.0M | — | ||
| Q2 24 | $18.0M | — | ||
| Q1 24 | $28.0M | — |
| Q4 25 | 18.8% | 31.1% | ||
| Q3 25 | 20.3% | 36.6% | ||
| Q2 25 | 22.0% | 37.3% | ||
| Q1 25 | 22.0% | 35.8% | ||
| Q4 24 | 21.5% | 34.6% | ||
| Q3 24 | 22.1% | 39.0% | ||
| Q2 24 | 21.0% | 38.2% | ||
| Q1 24 | 19.3% | 41.2% |
| Q4 25 | 7.6% | -5.2% | ||
| Q3 25 | 9.8% | 4.8% | ||
| Q2 25 | 10.6% | 6.5% | ||
| Q1 25 | 9.3% | -88.9% | ||
| Q4 24 | 7.3% | -5.1% | ||
| Q3 24 | 9.2% | 6.0% | ||
| Q2 24 | 7.6% | -6.3% | ||
| Q1 24 | 4.4% | 5.6% |
| Q4 25 | 15.3% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 3.8% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | $-0.34 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-2.55 | ||
| Q4 24 | — | $-0.43 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | — | $-0.27 | ||
| Q1 24 | $0.24 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.3B | $1.3B |
| Total DebtLower is stronger | $4.9B | — |
| Stockholders' EquityBook value | $3.4B | $14.7B |
| Total Assets | $13.2B | $37.2B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $2.1B | $975.3M | ||
| Q2 25 | $1.9B | $566.4M | ||
| Q1 25 | $1.9B | $755.0M | ||
| Q4 24 | $1.7B | $734.8M | ||
| Q3 24 | $871.0M | $1.9B | ||
| Q2 24 | $542.0M | $917.2M | ||
| Q1 24 | $252.0M | $1.0B |
| Q4 25 | $4.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.4B | $14.7B | ||
| Q3 25 | $2.3B | $15.2B | ||
| Q2 25 | $1.7B | $15.6B | ||
| Q1 25 | $1.5B | $15.7B | ||
| Q4 24 | $1.3B | $18.6B | ||
| Q3 24 | $611.0M | $19.8B | ||
| Q2 24 | $526.0M | $19.5B | ||
| Q1 24 | $289.0M | $20.0B |
| Q4 25 | $13.2B | $37.2B | ||
| Q3 25 | $9.9B | $37.9B | ||
| Q2 25 | $9.4B | $38.4B | ||
| Q1 25 | $8.9B | $38.5B | ||
| Q4 24 | $8.5B | $41.5B | ||
| Q3 24 | $7.4B | $44.8B | ||
| Q2 24 | $7.2B | $45.3B | ||
| Q1 24 | $7.0B | $47.3B |
| Q4 25 | 1.43× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $430.0M | $815.8M |
| Free Cash FlowOCF − Capex | $379.0M | $619.3M |
| FCF MarginFCF / Revenue | 6.8% | 16.8% |
| Capex IntensityCapex / Revenue | 0.9% | 5.3% |
| Cash ConversionOCF / Net Profit | 0.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | $889.0M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $430.0M | $815.8M | ||
| Q3 25 | $345.0M | $744.9M | ||
| Q2 25 | $29.0M | $219.7M | ||
| Q1 25 | $232.0M | $535.5M | ||
| Q4 24 | $60.0M | $482.7M | ||
| Q3 24 | $403.0M | $826.5M | ||
| Q2 24 | $354.0M | $379.1M | ||
| Q1 24 | $101.0M | $614.6M |
| Q4 25 | $379.0M | $619.3M | ||
| Q3 25 | $307.0M | $658.1M | ||
| Q2 25 | $-2.0M | $166.8M | ||
| Q1 25 | $205.0M | $492.9M | ||
| Q4 24 | $36.0M | $342.3M | ||
| Q3 24 | $376.0M | $749.5M | ||
| Q2 24 | $332.0M | $320.3M | ||
| Q1 24 | $83.0M | $564.8M |
| Q4 25 | 6.8% | 16.8% | ||
| Q3 25 | 5.4% | 17.6% | ||
| Q2 25 | -0.0% | 4.7% | ||
| Q1 25 | 4.8% | 15.2% | ||
| Q4 24 | 1.0% | 9.7% | ||
| Q3 24 | 10.3% | 20.1% | ||
| Q2 24 | 9.7% | 8.5% | ||
| Q1 24 | 2.7% | 15.5% |
| Q4 25 | 0.9% | 5.3% | ||
| Q3 25 | 0.7% | 2.3% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.6% | 1.3% | ||
| Q4 24 | 0.7% | 4.0% | ||
| Q3 24 | 0.7% | 2.1% | ||
| Q2 24 | 0.6% | 1.6% | ||
| Q1 24 | 0.6% | 1.4% |
| Q4 25 | 0.50× | — | ||
| Q3 25 | 2.28× | — | ||
| Q2 25 | 0.16× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 4.74× | — | ||
| Q2 24 | 19.67× | — | ||
| Q1 24 | 3.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVNA
| Used Vehicle Sales | $4.2B | 74% |
| Wholesale Sales And Revenues | $988.0M | 18% |
| Other | $459.0M | 8% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
